-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SOJ20rlwgOrsp2gcHB0TmcZ88RE0NWLTIBXtSwQPsaw69TCv1+qYezHPlFzoGJkY xzT1JHjXg3M8mhg7qeLpbg== 0000899243-00-000539.txt : 20000322 0000899243-00-000539.hdr.sgml : 20000322 ACCESSION NUMBER: 0000899243-00-000539 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20000321 GROUP MEMBERS: US ONCOLOGY INC GROUP MEMBERS: US ONCOLOGY RESEARCH INC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ILEX ONCOLOGY INC CENTRAL INDEX KEY: 0001001915 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 943123681 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-53221 FILM NUMBER: 574832 BUSINESS ADDRESS: STREET 1: 11550 IH-10 WEST SUITE 100 CITY: SAN ANTONIO STATE: TX ZIP: 78230 BUSINESS PHONE: 2109498200 MAIL ADDRESS: STREET 1: 14785 OMICRON DR SUITE 101 CITY: SAN ANTONIO STATE: TX ZIP: 78245 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: US ONCOLOGY INC CENTRAL INDEX KEY: 0000943061 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 841213501 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 16825 NORTHCHASE DR STREET 2: STE 1300 CITY: HOUSTON STATE: TX ZIP: 77060 BUSINESS PHONE: 2818732674 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN ONCOLOGY RESOURCES INC /DE/ DATE OF NAME CHANGE: 19950327 SC 13D/A 1 SCHEDULE 13-D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1 )* Ilex Oncology, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock - -------------------------------------------------------------------------------- (Title of Class of Securities) 451923 10 6 - -------------------------------------------------------------------------------- (CUSIP Number) Phillip H. Watts, Esq., 16825 Northchase Drive, Suite 1300, Houston, TX 77060. - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) March 8, 2000 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box [ ]. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent. (Continued on following pages) (Page 1 of Pages) - ---------- * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13D - ----------------------- --------------------- CUSIP NO. 451923 10 6 PAGE OF PAGES - ----------------------- --------------------- - ------------------------------------------------------------------------------ NAME OF REPORTING PERSON 1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON US Oncology Research, Inc. (formerly known as PRN Research, Inc.) ("PRNR") - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 2 (a) [_] (b) [_] - ------------------------------------------------------------------------------ SEC USE ONLY 3 - ------------------------------------------------------------------------------ SOURCE OF FUNDS* 4 Not Applicable - ------------------------------------------------------------------------------ CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] 5 - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 6 PRNR is a Texas corporation - ------------------------------------------------------------------------------ SOLE VOTING POWER 7 NUMBER OF 0 SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 8 0 OWNED BY ----------------------------------------------------------- EACH SOLE DISPOSITIVE POWER 9 REPORTING 0 PERSON ----------------------------------------------------------- SHARED DISPOSITIVE POWER WITH 10 0 - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 0 - ------------------------------------------------------------------------------ CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* 12 [_] - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 0% - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON* 14 CO - ------------------------------------------------------------------------------ *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. SCHEDULE 13D - ----------------------- --------------------- CUSIP NO. 451923 10 6 PAGE OF PAGES - ----------------------- --------------------- - ------------------------------------------------------------------------------ NAME OF REPORTING PERSON 1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON US Oncology, Inc. ("USON") - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 2 (a) [_] (b) [_] - ------------------------------------------------------------------------------ SEC USE ONLY 3 - ------------------------------------------------------------------------------ SOURCE OF FUNDS* 4 Not Applicable - ------------------------------------------------------------------------------ CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] 5 - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 6 USON is a Delaware corporation. - ------------------------------------------------------------------------------ SOLE VOTING POWER 7 NUMBER OF 0 SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 8 0 OWNED BY ----------------------------------------------------------- EACH SOLE DISPOSITIVE POWER 9 REPORTING 0 PERSON ----------------------------------------------------------- SHARED DISPOSITIVE POWER WITH 10 0 - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 0 - ------------------------------------------------------------------------------ CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* 12 [_] - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 0% - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON* 14 CO HC - ------------------------------------------------------------------------------ *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. CUSIP No. 451923 10 6 13D Page of Pages This Amendment No. 1 amends the Schedule 13D filed by the reporting persons dated August 18, 1999 (the "Schedule"). This Amendment No. 1 is being filed because the Reporting Persons are no longer subject to the reporting requirements of Section13(d) of the Securities Exchange Act of 1934 as a result of the disposition of the 1,255,988 shares of common stock ($.01 par value) of ILEX Oncology, Inc. previously held by PRNR (the "Shares") pursuant to a sale of the Shares on March 8, 2000. Other than as set forth below, to the best knowledge of the Reporting Persons, there has been no material change in the information set forth in response to Items 1, 3,6 and 7 of the Schedule. Accordingly, these Items are omitted from this Amendment No. 1. ________________________________________________________________________________ Item 2. Identity and Background. (a) This Statement is filed by US Oncology, Inc. and US Oncology Research, Inc. (formerly known as PRN Research, Inc.) (collectively, the "Reporting Persons"). (b) The principal executive offices of the Reporting Persons are located at 16825 Northchase Drive, Suite 1300, Houston, Texas 77060. (c) The Reporting Persons provide practice management, administrative and other services to physician groups specializing in the treatment of cancer. PRNR is an indirect wholly owned subsidiary of USON focusing on research activities of managed groups. Information regarding the foregoing with respect to each of the Officers and Directors of each of the Reporting Persons is set forth on Schedule A to this Schedule 13-D. (d) Neither of the Reporting Persons, nor, to the knowledge of the Reporting Persons, any of the individuals named on Schedule A hereto, has been convicted in a criminal proceeding in the past five years (excluding traffic violations or similar misdemeanors). (e) During the past five years, neither of the Reporting Persons, nor, to the knowledge of the Reporting Persons any of the individuals named on Schedule A hereto, was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws of finding any violation with respect to such laws. (f) Each of the officers and directors of the Reporting Persons is a United States citizen. ________________________________________________________________________________ Item 4. Purpose of Transaction. Not Applicable ________________________________________________________________________________ Item 5. Interest in Securities of the Issuer. (a) As a result of the disposition of 1,255,988 shares of common stock ($.01 par value) of the Issuer pursuant to the sale of such shares on March 8, 2000, the Reporting Persons do not beneficially own any shares of common stock ($.01 par value) of the Issuer. (b) The Reporting Persons do not have the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition or shared power to dispose or to direct the disposition of common stock ($.01 par value) of the Issuer. (c) Other than the transaction described in this Amendment No. 1, there were no transactions by any of the Reporting Persons, persons in control of the Reporting Persons or any of their respective officers and directors in the common stock ($.01 par value) of the Issuer that were effected during the past sixty days. (d) To the best knowledge of the Reporting Persons, no person other than the Reporting Persons has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock ($.01 par value) of the Issuer that occurred on March 8, 2000. (e) The Reporting Persons ceased to be the beneficial owner of more than five percent of the common stock ($.01 par value) of the Issuer on March 8, 2000. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. US Oncology Research, Inc. /s/ L. FRED POUNDS - -------------------------------- Dated: March 20, 2000 L. Fred Pounds, Treasurer and --------------------- Secretary US Oncology, Inc. /s/ L. FRED POUNDS - --------------------------------- Dated: March 20, 2000 L. Fred Pounds, Chief Financial Officer --------------------- and Vice President of Finance. Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001). Schedule A ---------- Officers and Directors of US Oncology Research, Inc. - ---------------------------------------------------- R. Dale Ross President and Director Lloyd K. Everson, M.D. Vice President and Director L. Fred Pounds Treasurer and Secretary and Director Executive Officers of US Oncology, Inc. - --------------------------------------- R. Dale Ross Chairman of the Board and Chief Executive Officer Lloyd K. Everson, M.D. President L. Fred Pounds Chief Financial Officer, Vice President of Finance and Treasurer Leo E. Sands Chief Compliance Officer David Chernow President, Physician Services Group and Chief Development Officer Joseph S. Bailes, M.D. Executive Vice President R. Allen Pittman Chief Administrative Officer Atul M. Dhir, M.D. President, Cancer Information and Research Group William F. McKeon Senior Vice President for Marketing and eCommerce Phillip H. Watts General Counsel Marc I. Kerlin Senior Vice President for Managed Care Mark E. Ahern Senior Vice President for Development The present business address of all of the foregoing individuals is 16825 Northchase Drive, Suite 1300, Houston, Texas 77060. Directors of US Oncology, Inc. - ------------------------------
Name Present Business Address Present Principal Occupation R. Dale Ross 16825 Northchase Drive, Suite 1300, Chief Executive Officer, US Houston, Texas 77060 Oncology, Inc. Nancy Brinker 9410 Alva Court CEO - In Your Corner, Inc., a provider of health Dallas, Texas 75229 and wellness products and services Russell L. Carson 320 Park Avenue, Suite 2500 Partner - Welsh, Carson, Anderson & Stowe, an New York, New York 10022 investment partnership John T. Casey 16825 Northchase Drive, Suite 1300, Former Chief Executive Officer, Physician Reliance Houston, Texas 77060 Network, Inc., now a part time employee of physician Reliance Network, Inc. J. Taylor Crandall 201 Main Street Vice President and CFO of Keystone, Inc., an Fort Worth, TX 76102 investment company. James E. Dalton, Jr. 103 Continental Place President, CEO and Director of Quorum Health Brentwood, Tennessee 37207 Group, Inc., a health care company Robert W. Daly 36 Washington Stret, Suite 170 Managing Director, MedEquity Investors, LLC, a Wellesley Hills, MA 02481 health care venture capital firm. Stephen E. Jones, M.D. 3535 Worth Street Physician, Texas Oncology, P.A. Dallas, Texas 75246 Richard B. Mayor 700 Louisiana Ave, Ste. 1900 Of Counsel, Mayor, Day, Caldwell & Keeton, L.L.P. Houston, Texas 77002 Robert A. Ortenzio 4718 Old Gettysburg Road President and Chief Operating Officer, Select Mechanicsburg, PA 17055 Medical Corporation Boone Powell, Jr. 3500 Gaston Avenue President and Chief Executive Officer, Baylor Dallas, TX 75246 Health Care System and Baylor University Medical Center Edward E. Rogoff, M.D. 2625 Craycroft Road, Suite 100 Physician, Southwestern Radiation Oncology, Ltd. Tucson, AZ 85712 Burton S. Schwartz, M.D. 800 E. 25th Street Physician, Minnesota Oncology Hematology, P.A. 405 Piper Bldg. Minneapolis, Minnesota 55407
-----END PRIVACY-ENHANCED MESSAGE-----